Edition:
United States

Spark Therapeutics Inc (ONCE.OQ)

ONCE.OQ on NASDAQ Stock Exchange Global Select Market

88.49USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$88.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
214,557
52-wk High
$93.97
52-wk Low
$41.06

Latest Key Developments (Source: Significant Developments)

Spark Therapeutics Reports Q1 Loss Per Share Of $1.25
Tuesday, 8 May 2018 07:30am EDT 

May 8 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS.Q1 LOSS PER SHARE $1.25.Q1 EARNINGS PER SHARE VIEW $-0.34 -- THOMSON REUTERS I/B/E/S.Q1 REVENUE $15.7 MILLION.Q1 REVENUE VIEW $53.9 MILLION -- THOMSON REUTERS I/B/E/S.$587.5 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018.  Full Article

Spark Therapeutics Enters Into A Spk-9001 Manufacture And Supply Agreement With Pfizer
Tuesday, 20 Feb 2018 08:22am EST 

Feb 20 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS INC - ON FEB 16, CO ENTERED INTO A SPK-9001 MANUFACTURE AND SUPPLY AGREEMENT WITH PFIZER - SEC FILING.SPARK THERAPEUTICS SAYS UNDER AGREEMENT, PFIZER WILL PAY CO $7 MILLION UPON EXECUTION OF AGREEMENT - SEC FILING.SPARK THERAPEUTICS INC - THE AGREEMENT IS TO MANUFACTURE AND DELIVER TO PFIZER SPARK-9001 BULK DRUG SUBSTANCE.SPARK THERAPEUTICS INC - UNDER AGREEMENT, PFIZER MAY MAKE A SECOND PAYMENT TO CO OF UP TO $7 MILLION.SPARK THERAPEUTICS INC - CO WILL BEGIN SPARK-9001 BULK DRUG SUBSTANCE MANUFACTURE IN THE FIRST QUARTER OF 2018.  Full Article

Spark Therapeutics Reports Cash And Cash Equivalents And Marketable Securities Of $540.2 Mln As Of Dec. 31, 2017
Tuesday, 20 Feb 2018 07:30am EST 

Feb 20 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS.SPARK THERAPEUTICS INC - AS OF DEC. 31, 2017, SPARK HAD CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $540.2 MILLION.  Full Article

Spark Therapeutics To Begin Program In Pompe Disease
Monday, 8 Jan 2018 06:24pm EST 

Jan 8 (Reuters) - Spark Therapeutics ::SPARK THERAPEUTICS CEO SAYS PLANS TO BEGIN PROGRAM IN POMPE DISEASE.SPARK CEO SAYS EXPECTS LUXTURNA GENE THERAPY TO BE AVAILABLE TO PATIENTS IN EUROPE IN 2019.  Full Article

Spark Therapeutics - On Jan 3, 2018, Co Announced Wholesale Acquisition Cost For Luxturna Is $425,000/Dose
Wednesday, 3 Jan 2018 09:00am EST 

Jan 3 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS - ON JAN 3, 2018, CO ANNOUNCED WHOLESALE ACQUISITION COST FOR LUXTURNA (VORETIGENE NEPARVOVEC-RZYL) IS $425,000/DOSE OR PER EYE.  Full Article

FDA Approves Luxturna, A Gene Therapy To Treat A Rare Form Of Vision Loss
Tuesday, 19 Dec 2017 10:43am EST 

Dec 19 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVES LUXTURNA (VORETIGENE NEPARVOVEC-RZYL), A GENE THERAPY TO TREAT PATIENTS WITH A RARE FORM OF INHERITED VISION LOSS.U.S FDA SAYS GRANTED APPROVAL OF LUXTURNA TO SPARK THERAPEUTICS INC.U.S. FDA SAYS LUXTURNA IS APPROVED FOR THE TREATMENT OF PATIENTS WITH CONFIRMED BIALLELIC RPE65 MUTATION-ASSOCIATED RETINAL DYSTROPHY.  Full Article

Spark Therapeutics reports Q3 loss per share $1.90
Tuesday, 7 Nov 2017 07:30am EST 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics Inc reports third quarter 2017 financial results and recent business progress.Q3 loss per share $1.90.Q3 earnings per share view $-1.81 -- Thomson Reuters I/B/E/S.  Full Article

Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
Tuesday, 7 Nov 2017 07:15am EST 

Nov 7 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B.Spark Therapeutics Inc - Co transferring enhanced SPK-9001 manufacturing process to Pfizer.Spark Therapeutics - Co, Pfizer ‍have entered into amendment to their license agreement for SPK-9001.Spark Therapeutics - ‍Subject to terms of amendment, Spark Therapeutics will receive from pfizer an initial $10 million cash payment​.Spark Therapeutics Inc - Will enroll up to five additional participants in current phase 1/2 clinical trial​.Spark - ‍Subject to amendment, to receive from Pfizer up to additional $15 million in potential milestone payments upon completion of transition activities​.Spark Therapeutics - ‍Activities outlined in amended agreement will occur parallel to Pfizer's ongoing preparation to assume responsibility for SPK-9001.  Full Article

Spark Therapeutics says NASDAQ halts trading of its common stock
Thursday, 12 Oct 2017 07:30am EDT 

Oct 12 (Reuters) - Spark Therapeutics Inc : :Spark Therapeutics (once) trading of stock halted as FDA advisory committee reviews investigational gene therapy.Spark Therapeutics Inc - U.S. ‍FDA's cellular, tissue and gene therapies advisory committee is meeting today to review LUXTURNA (voretigene neparvovec)​.Spark Therapeutics Inc - ‍LUXTURNA is under priority review with FDA, with an assigned prescription drug user fee act (PDUFA) date of jan. 12, 2018​.  Full Article

Spark Therapeutics enters into licensing agreement with Genethon
Wednesday, 20 Sep 2017 07:30am EDT 

Sept 20 (Reuters) - Spark Therapeutics Inc :Spark Therapeutics enters into licensing agreement with Genethon.Spark Therapeutics Inc - ‍specific genetic target and financial terms of agreement have not been disclosed​.Spark Therapeutics Inc -co ‍ has option to develop and commercialize any gene therapy that results from licensing agreement​.Spark Therapeutics Inc - under terms of agreement, Genethon will collaborate with Spark Therapeutics on further preclinical research activities.  Full Article

BRIEF-Spark Therapeutics Reports Q1 Loss Per Share Of $1.25

* SPARK THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS